Developing a new treatment for lung injury caused by radiation exposure
Official title: THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE
Funded at Innovation Pathways, LLC · NIH-11111142 · Data updated 2026-11-12
This study is looking at how a special drug called IPW-5371 Fumarate might help protect lung health after radiation exposure, using animal models to find out if it can reduce lung damage, with hopes that it could lead to new treatments for people in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Innovation Pathways, LLC NIH-funded |
| Lab location | 1 site (Palo Alto, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,499,864 |
| NIH project number | 75N93023C00014-P00003-9999-1 |
| Project ID | NIH-11111142 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals who have experienced radiation exposure and are at risk of developing lung injuries.
✕Less likely to help
Patients who have not been exposed to radiation or do not have lung injury concerns may not benefit from this research.
What this research studies
This research investigates the effects of radiation exposure on lung health using animal models. It focuses on a specific drug, IPW-5371 Fumarate, which aims to mitigate the delayed effects of radiation-induced lung injury. The study follows FDA guidelines to ensure that the findings can support future human applications. By understanding how this drug interacts with the body after radiation exposure, the research hopes to pave the way for effective treatments.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients suffering from lung injuries caused by radiation exposure.
How similar studies have gone: While this approach is novel in the context of lung injury from radiation, similar pharmacological interventions have shown promise in other areas of radiation medicine.
Where this research is happening
-
Innovation Pathways, LLC
Palo Alto, United States Active
Researchers
- Principal investigator: Hart, Barry — Innovation Pathways, LLC
- Study coordinator: Hart, Barry
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.